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Bioresorbable Vascular Scaffolds in Coronary Interventions: 6-Month Results
From the German ASSURE-Registry
Detlef Mathey1
1Hamburg University Cardiovascular Center, Hamburg, Germany
Background: Bioresorbable vascular scaffolds have been available on the European
market since November 2011. The ﬁrst experience in a real-world setting is being
documented in the ASSURE registry (NCT01583608). The registry aims to investi-
gate the safety, efﬁcacy and performance of the everolimus-eluting, bioresorbable
vascular scaffold (BVS, ABSORB, Abbott Vascular Inc., Santa Clara, CA) over
a period of 3 years.
Methods: Consecutive patients with de novo native coronary artery disease were
treated with BVS at 6 German centers and included in the prospective, observational
registry. Acute and 6-months outcomes of equal weight were device success, proce-
dural success, cardiac death, myocardial infarction, ischemia driven target lesion
revascularization and target vessel failure or revascularization. Angiographic param-
eters were assessed at baseline and post procedure.
Results: A total of 183 patients (63.5  9.3 years, 79.8% male) were enrolled from
April 2012 to March 2013 and 198 lesions were treated. Eligibility criteria for
ABSORB A/B would have been met in 16% and for ABSORB EXTEND in 70% of
the patients. Acute device success was achieved in 194 (98%) lesions and acute
procedural success in all patients. No cardiac death or myocardial infarction occurred
and no target lesion revascularization was necessary during hospital stay. Median
lesion length was 14.5 mm (5-84 mm) with 85 (42.9%) lesions > 20 mm. 31 (15.7%)
lesions were moderately or heavily calciﬁed, 6 (3%) lesions were tightly angulated and
6 (3%) lesions involved a side branch  2 mm in diameter. Diameter stenosis was
77.9% at baseline and 4.8% post PCI on average. In 11 (5.6%) lesions diameter of
stenosis was  99%. The reference vessel diameter of 32 (16.2%) lesions was  2.5
mm. In 30 (15.2%) lesions > 1 BVS was implanted and in 11 patients > 1 target
vessel was treated. Bailout with a drug eluting stent was necessary in 3 (1.5%) lesions.
Conclusions: Acute results for safety, efﬁcacy and performance of BVS for de novo
coronary artery disease in all day clinical practice are promising. Angiographic core lab
results will be obtained by June 2013 and clinical 6-months results by September 2013.
TCT-422
Malapposition is observed more frequently and to a greater degree in
ﬁbrocalciﬁc plaques during bioresorbable vascular scaffold implantation
Liam M. McCormick1, Adam J. Brown1, Denise M. Braganza1, Stephen P. Hoole1,
Nick E. West1
1Papworth Hospital NHS Trust, Cambridge, United Kingdom
Background: The bioresorbable vascular scaffold (BVS) has several advantages over
existing metallic stents, including resorption and restoration of vasoreactivity.
However, the mechanical properties of the BVS do not allow aggressive post-dila-
tation, with potential for malapposition. Our aim was to assess the incidence of
malapposition and relation to plaque characteristics.
Methods: 22 patients undergoing BVS implantation were included (77.3% male; age
60.111.2yrs). Optical coherence tomography (OCT) was performed before/after
implantation. Two experienced OCT operators analyzed runs at 1mm longitudinal
intervals; where malapposition was seen, analysis was performed at 0.2mm intervals.
Malapposition was adjudicated and quantiﬁed, deﬁned as strut with 50% contact of
abluminal strut surface with endothelium. Tissue characterisation was deﬁned as the
predominant plaque composition in the quadrant of each strut. The degree of mal-
apposition was measured from adluminal strut edge to endothelium in a radial
direction, with strut width being 0.158mm.
Results: Target lesion was LAD 12, RCA 6, Cx 2 and SVG 2. Calciﬁcation was
absent (81.8%), mild (4.5%) and moderate (13.6%) on independent review. Median
number of BVS implanted was 1 (median size 3.0x18mm). Agreement on OCT-
deﬁned strut malapposition between observers was excellent (Kappa 0.847). In total,
766 frames of OCT were analysed (median 29.5 per case). 6798 struts were identiﬁed
with 436 (6.85%) being malapposed. Number of malapposed struts varied signiﬁ-
cantly (range 0-147, median 5, IQR 1-29). Fibrocalciﬁc plaque was more prevalent
when malapposition was present (46.6% vs. 8.3%, p<0.001). There was a positive
correlation between %calciﬁcation and malapposition (r¼0.44, p<0.001). The
distance of malapposition in ﬁbrocalciﬁc plaque was increased compared to other
malapposed struts (0.17mm0.10 vs. 0.14mm0.07, p¼0.01).
Conclusions: Incidence of strut malapposition with BVS is comparable to existing
DES platforms. However, malapposition is more frequent and occurs to a greaterJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrdegree in ﬁbrocalciﬁc plaques. Intracoronary imaging should be considered prior to
BVS, as unrecognized calciﬁcation may lead to unnecessary malapposition.
TCT-423
Bifurcation Strategies with the Absorb BVS Everolimus-Eluting Resorbable
Scaffold. A Bench Study
Jonathon White1, John A. Ormiston2, Ben Ubod3, Bruce Webber3, Mark W. Webster4
1Auckland Hospital, Auckland, New Zealand, 2Associate Professor, University of
Auckland Medical School, Auckland, New Zealand, 3Mercy Angiography, Auckland,
New Zealand, Auckland, New Zealand, 4AucklandCityHospital,Auckland,NewZealand
Background: While bifurcation stenting techniques with metallic stents have been
extensively studied on the bench and clinically, there are no data on how to treat
bifurcations with Absorb everolimus-eluting bioresorbable scaffolds (BRS) which have
limited post-dilatation potential without strut rupture compared with metallic scaffolds.
Methods: BRS were deployed in phantoms with 30, 60 and 90 side-branch angles in
water at 37C for testing strategies including side-branch dilatation with 2.5 and 3.0mm
balloons, main branch post-dilatation, kissing post-dilatation at 4 atmospheres pressure
and minimal balloon overlap, proximal optimization, "T" stenting with BRS and with
metallic stents, "T" with protrusion, Culotte technique, "Crush" technique, SKS technique.
The deployment steps were recorded using cine-angiography and ﬁnal results of each
technique were recorded photographically and withmicro-computed tomographic images.
Results: Dilating through the side of a BRS produced distortion similar to that with
metallic stents that was worse with smaller side-branch angles and bigger balloons.
The distortion consisted of narrowing of the scaffold beyond the side-branch and
malapposition of the struts opposite the side branch. The positive effect of distortion
occurred, with protrusion of struts into the side-branch. The distortion could be
partially repaired by main branch post-dilatation but was best repaired by low pressure
kissing post-dilatation. An unique feature of BRS use in bifurcations is the occurrence
of single scaffold hoop or connector rupture. These are of uncertain signiﬁcance.
Conclusions: Bench deployments of BRS provide insights into bifurcation strategies
with these unique devices that behave differently from metallic scaffolds.
TCT-424
Bifurcation Bench Testing With The Bioresorable Vascular Scaffold:
Implications For Clinical Use.
Pieter C. Smits1, Nic Debusschere2, Kees-Jan Royaards3, Matthieu De Beule4,
Peter Mortier4
1Maasstad Hospital Rotterdam, Rotterdam, Netherlands, 2Ghent University, Ghent,
Belgium, 3Maasstad Hospital, Rotterdam, Netherlands, 4FEops / Ghent University,
Gent, Belgium
Background: Little is known about bifurcation treatment with the bioresorable
vascular scaffold (BVS) from Abbott. In a bench test we investigated the mechanical
properties and integrity of BVS in different bifurcation models
Methods: In a warm water bath of 36 degrees Celsius multiple BVS were tested in 2
models. Model A. Opening towards an artiﬁcial side branch (SB) of a 3.0 mm BVS
was investigated with increasing balloon sizes through a mid BVS cell under an angle
of 30 and 60 degrees. Model B. With a 3D printer, 6 bifurcation models consisting of
a rubber-like material (TangoPlus) with moderate stenosis (Medina 1-1-0) and 60
degree SB angle were made with the proper sizing of the proximal main branch
(PMB), SB and distal main branch (DMB) using a validated scaling law. In these
models 2.5, 3.0 and 3.5 mm BVS were implanted in the MB. Sequentially, SB
opening was done using single 2.0 or 2.5 mm balloons (4 models) or using 2.0 and 3.0
mm balloons for complete (1 model) and incomplete kissing/snuggle (1 model).
Opening and distortion of the BVS struts were investigated with OCT and microCT.
Results: In model A, without surrounding structures, a cell of a 3.0 mm BVS can be
expanded with 1.5 and 2.5 mm balloons at high pressure (16 atm) without disrupting
struts. With a 3.0 balloon at 30 degree angle at 10 atm. and with 3.5 balloon at 60
degree angle at 8 atm. 1 or more struts ruptured. In model B, all 3D models showed no
strut ruptures by OCT. By microCT only one partial strut tear was seen after
incomplete kissing balloon. By OCT and microCT identical scaffold distortions of the
PMB and DMB were observed, similar to what has been described with metallic
stents. Distal struts adjacent to the SB were deﬂected into the lumen and proximal
struts adjacent to the SB were deﬂected towards the SB opening. Furthermore, struts
opposite the SB were deﬂected inwards causing malapposition. Increasing SB balloon
size showed increased malapposition up to 270 um. With double balloon inﬂation
technique no malapposition was noted.
Conclusions: These results support the concept that bifurcation treatment with BVS is
feasible and that similar strategies for provisional sidebranch treatment apply as to
metallic stent.
TCT-425
Real-World Experience with Absorb Bioresorbable Scaffold Technology -
Early Australian Registry Results
Nigel Jepson1, Clare Arnott1, Liam Back1, Sze-yuan Ooi1, Mark Pitney2
1Prince of Wales Hospital, Sydney, NSW, 2Sutherland Hospital, Sydney, NSW
Background: The safety and efﬁcacy of the Absorb bioresorbable scaffold (ABS)
has been documented in lower-risk lesion subsets however outcome data in moreacts/POSTER/Bioresorbable Vascular Scaffolds B131
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from two Australian centres.
Methods: Between Aug 2010-Jun 2013, 95 lesions in 68 pts were treated with ABS
(64% male, mean age 63 yrs). Diabetes was present in 22% and PCI indication was
ACS in 32% pts. Lesion location was 46% LAD, 41.5% RCA, 10% RCA and 2.5%
SVG. Lesion complexity was 42% B2 or C, 19% moderate/severe calciﬁcation, 4%
CTO, 27% long lesions and 7% bifurcations. Pre-dilatation was used in 100% pts
(rotablator/scoring balloon in 4%). In total, 107 scaffolds were implanted - average
1.6/pt (range 1-5) with average scaffold length/pt 39mm. Scaffold overlap was per-
formed in 31% pts. Multivessel ABS implantation was performed in 8.8% pts. Post-
dilatation was performed in 100% cases. Registry data was collected prospectively in
hospital, day 30, 1 and 2 years post-PCI. To date, 87% of pts have reached 30 days,
34% 12 months and 4% 24 months post-ABS implantation.
Results: Procedural success was 100% and device success 99% (failure to deliver
ABS in 1 pt). A "bail-out" DES was required in 2 (3%) of cases for scaffold edge
dissection. An in-hospital non-Q MI occurred in 1 (1.5%) pt due to athero-thrombotic
distal embolism. There were no other in-hospital clinical events (target vessel revas-
cularization, Q wave MI, scaffold thrombosis or any death). There have been no late
cases of MI (Non-Q or Q wave), target vessel revascularization, scaffold thrombosis or
cardiac death. There was 1 (1.5%) non-cardiac death at 21 months post-ABS
implantation due to renal failure. Overall MACE in late follow-up occurred in 2
(2.9%) pts.
Conclusions: This early Australian experience has demonstrated very high immediate
ABS success in the treatment of complex coronary disease. Additionally, ABS therapy
following rigorous lesion preparation and strict implantation technique is highly safe
and efﬁcacious both in-hospital and in follow-up in "real-world" disease (including
long lesions, CTOs, calciﬁcation, bifurcations and muti-vessel disease).TCT-426
Our Experience With Absorb Everolimus Eluting Bioresorbable Vascular
Scaffold in All Comers with Coronary Artery Disease –“Real Absorb Registry”.
Ashok Seth1, Vinayak Ravisekar2, Vishal Rastogi3, Vijay Kumar4, Upendra Kaul5,
Atul Mathur3, Praveer Agarwal3, Vinay Sanghi6
1Fortis Escorts Heart Institute, Okhla Road, New Delhi 110025 (India), New Delhi,
India, 2Fortis escorts heart institute, New Delhi, India, 3Fortis Escorts Heart Institute,
New Delhi, India, 4Fortis Escorts Heart institute, New delhi, India, 5Fortis Escorts
Heart Institute, New Delhi, ID, 6Fortis Escorts Heart Institute, New Delhi, OR
Background: The experience of the BVS in real world patients with expanded
indications and lesion characterization is limited. We report our experience of the use
of BVS in real world all comers patients from the "Real Absorb Registry".
Methods: Our "Real ABSORB registry" is a single centre registry of all BVS
implanted in real life patients since its approval for unrestricted clinical use in
December 2012 onwards.
Results: Out of 135 patients with 165 lesions were treated with 217 BVS.111 patients
with 189 BVS were outside the Absorb extend criteria. The lesion characteristics are
as follows 40%(54/135) had calciﬁed lesion (CL), 8.8%(12/135) tortuous lesions with
>2 45/>90 angulation.37% (50/135) had Bifurcation lesions (BL),28.8%(39/135)
had long lesion ( one 28 mm Absorb), 20.7%(28/135) had small vessels (<2.5 mm),
9.6%(13/135) had chronic total occlusion, 11.8%(16/135) had ostial involvement and
8.1%(11/135) had ISR. In CL, 11.1%(15/135) required Rotablation and 2.2%(3/135)
had cutting balloon for bed preparation. 11.8%(16/135) required buddy wire for
device delivery. 2.9%(4/135)BVS failed to deliver due to calciﬁed tortuosity and
required Guideliner, catheter. In BL 14%(7/50) had planned 2 stent strategy and
86%(43/50) had provisional single stent strategy.6.9%(3/43)had SB stenting with TAP
technique due to threatened closure. OCT/IVUS done in 17.7%(24/135) and helped to
optimize the result in only 2 patients. All BVS had high pressure dilatation >20 atm
within the recommended limitations of BVS expansion All BVS were deployed
successfully. There is no acute/sub acute thrombosis. 130/135 patients had clinical
follow up and 1(0.7%) patient had sudden death at 50 days of follow up(median 143
days,range 17-163).
Conclusions: Our early experience from the Real Absorb Registry of all the use of
BVS in real world patients suggest high success and low complication rates provided
there is meticulous attention to delivery and implantation techniques. While regular
use of imaging tools may help especially in complex patients, We believe that routine
and regular use of extensive high pressure implantation to be more valuable in opti-
mizing results and avoiding scaffold thrombosis in all real world patients.B132 JACC Vol 62/18/Suppl B j October 27–NovembTCT-427
Comparison of Acute Stent Recoil Between the Everolimus-Eluting
Bioresorbable Vascular Scaffold and Two different Drug-Eluting Metallic Stents
Tarcisio Campostrini1, Jose d. Costa Jr,2, Alexandre Abizaid3, Andrea Abizaid4,
Daniel Chamié5, Rodolfo Staico2, Ricardo A. Costa6, Mateus Veloso e Silva7,
Dimytri A. Siqueira8, Fausto Feres4, Danillo Taiguara R Silva9, Amanda Sousa5,
J Eduardo Sousa5
1Instituto Dante Pazzanese de Cardiologia, São Paulo, São Paulo, 2Instituto Dante
Pazzanese de Cardiologia, São Paulo, Brazil, 3Instituto Dante Pazzanese de
Cardiologia, São Paulo, São Paulo, 4N/A, São Paulo, Brazil, 5Dante Pazzanese, São
Paulo, Brazil, 6Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil,
7Instituto Dante Pazzanese de Cardiologia, São Paulo, São Paulo, 8Dante Pazzanese
Institute of Cardiology, São Paulo, SP, 9Dante Pazzanese Institute of Cardiology, Sao
Paulo, Brazil
Background: Recently, bioresorbable scaffolds (BRS) have been developed as a way
to provide transient vessel scaffold while the post PCI healing process takes place,
going away just after. Among the various BRS in clinical test, the most advanced
program is the ABSORB, which combines a PLLA backbone, coated with a bio-
resorbable polymer containing the antiproliferative drug, everolimus. Because this
BRS is made of polymer, concerns about in human acute recoil have been raised. We
sought to assess the acute recoil of two different metallic DES in comparison to
ABSORB in the treatment of non-complex coronary lesions
Methods: For this study we included 50 patients with de novo lesion in native
coronary arteries of 2.5-3.5mm in diameters and lesion length up to 23mm. Twenty-
ﬁve patients were treated with BRS and compared to 25 patients treated with either
everolimus-eluting cobalt chromium stent (EES, n¼12) or biolimus-eluting stainless
steel stent (BES, n¼13) at a random allocation. Acute absolute recoil was deﬁned as
the difference between mean diameter of the last inﬂated balloon at the highest
pressure (X) and mean lumen diameter of the stent immediately after the last balloon
deﬂation (Y). Acute percent recoil was deﬁned as (X – Y)/X and expressed as
percentage
Results: The 3 cohorts did not differ regarding the basic clinical and angiographic
characteristics. Mean lesion length (11.74  3.91mm in the BRS vs. 10.12 
3.21mm in EES vs. 12.93  5.7mm in the BES cohort, p¼0.7) and RVD (2.62 
0.44mm in the BRS vs. 2.74  0.34mm in the EES vs. 2.59  0.42mm in the BES
group, p¼0.4) were also comparable as well as the rate of post dilatation and balloon
to artery ratio. Notably, acute absolute recoil (0.21  0.13mm with BRS vs. 0.15 
0.08mm with EES and 0.14  0.08mm with BES, p¼0.4) and acute percent
recoil (7.0  4.64% with BRS vs. 4.97  2.22% with EES and 5.66  4.10% with
BES, p¼0.2) did not signiﬁcantly differ from different metal alloys and polymeric
scaffolds
Conclusions: In this small, non-complex cohort, the use of a polymeric scaffold did
not result in higher acute recoil as compared to the two most used metallic alloys. This
ﬁnding should be investigated in more complex scenariosTCT-428
Rate of bioresorbable vascular scaffolds penetration in the treatment of coronary
artery disease in a Canadian high-volume center
Samer Mansour1, Ramez El Khoury2, François Gobeil1, Jean Bernard Masson2,
Andre Kokis3
1University of Montreal, Montreal, Quebec, 2Centre Hospitalier de l'Université de
Montréal, Montreal, Quebec, 3Centre Hospitalier de l'Université de Montréal,
Montréal, Quebec
Background: Vascular restoration therapy using bioresorbable vascular scaffolds
(BVS) is a novel approach for treating coronary disease. However, BVS penetration
rate in the treatment of de-novo coronary stenosis in the real life setting is unknown.
Methods: One hundred BVS were available to be used by 6 trained operators between
November 2012 and March 2013 in a high-volume center. Therefore, consecutive
patients treated by the same operators with drug-eluted stents (DES) or BVS were
prospectively analyzed.
Results: Two hundred and forty-ﬁve consecutive DES/scaffolds implantation to treat
144 patients were performed. Thirty-six BVS (15%) were only used in 24 patients
(17%) as compared to 209 DES (85%) used to treat 120 patients (83%). Patients
treated with BVS were younger (6011 vs. 6512 years; p<0.012), had less diabetes
(21% vs. 53%; p<0.001), less type B2/C lesions (28% vs. 60%; p<0.001) and
necessitate less scaffolds (1.50.7 vs. 1.70.9; p¼0.032) as compared to the DES
patients respectively. The reason of non-BVS implantation was documented at the end
of each case and was as follow: unavailable BVS length i.e. longer than 28mm and
lesion could be covered by one DES (23%); bifurcating lesions involving a side
branch of 2mm diameter or more (17%,); unavailable BVS diameter i.e. superior to
3.5mm (17%); severely calciﬁed lesions (17%); chronic total occlusion lesions (11%);
intrastent restenosis (7%); ST-elevation myocardial infarction with thrombus (6%);
others such as venous graft or multiple previous stenting (2%).
Conclusions: The main direct reason for the lack of BVS take-up is the lesion
complexity. However, indirect unmeasured reasons such as cost, operator experience
or lack of evidence on long-term follow-up can also interfere with the treating
physician decision. Randomised studies showing the beneﬁcial long-term follow-up of
BVS to treat more complex lesions are warranted.er 1, 2013 j TCT Abstracts/POSTER/Bioresorbable Vascular Scaffolds
